Open access
Open access
Powered by Google Translator Translator

Oncology – Urological

Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma.

24 Jun, 2022 | 10:46h | UTC

Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

News Release: Non-invasive liquid biopsy tracks cancer treatment success in real time – University of Wisconsin–Madison

Commentary: Longitudinal Liquid Biopsy for Circulating Tumor Cells in Metastatic Renal Cell Carcinoma – The ASCO Post

 

Commentary on Twitter

 

ASCO Guideline: Management of metastatic clear cell renal cell carcinoma.

22 Jun, 2022 | 11:30h | UTC

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline – Journal of Clinical Oncology

 

Long-term follow-up of a RCT: Nivolumab plus cabozantinib vs. sunitinib in first-line treatment for advanced renal cell carcinoma.

22 Jun, 2022 | 10:48h | UTC

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: CheckMate 9ER update confirms first-line nivolumab plus cabozantinib benefits for advanced RCC – medwire News

Original Study: Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma – New England Journal of Medicine

 

Commentary from the author on Twitter (thread – click for more)

 

Consensus definition and management recommendations: intermediate-risk non–muscle-invasive bladder cancer.

21 Jun, 2022 | 10:52h | UTC

Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group – European Urology – Oncology (if the link is paywalled, try this one)

 

Commentary from the author on Twitter

 

RCT: Active surveillance plus Enzalutamide monotherapy vs. active surveillance alone in patients with low-risk or intermediate-risk localized prostate cancer.

21 Jun, 2022 | 10:33h | UTC

Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer – JAMA Oncology

Invited Commentary: To Treat or Not to Treat Men With Low-risk or Intermediate-risk Prostate Cancer—Weighing the Evidence – JAMA Oncology (free for a limited period)

Video criticizing the article: ENACT trial | A Study That Makes Pharma Rich and Patients’ Poor | I break it down – by Vinay Prasad

 

Commentaries on Twitter

 

Single-arm phase 2b study: MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer.

20 Jun, 2022 | 00:56h | UTC

MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study – The Lancet Oncology (link to abstract – $ for full-text)

News Release: High-intensity focused ultrasound (HIFU) can control prostate cancer with fewer side effects – Memorial Sloan Kettering Cancer Center

 

Commentary on Twitter

 

Long-term results of RCT: Radiotherapy to the prostate for men with metastatic prostate cancer.

10 Jun, 2022 | 11:10h | UTC

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial – PLOS Medicine

 

New study associates intake of dairy milk with greater risk of prostate cancer.

10 Jun, 2022 | 10:50h | UTC

News Release: New study associates intake of dairy milk with greater risk of prostate cancer – Loma Linda University Adventist Health Sciences Center

Original Study: Dairy foods, calcium intakes, and risk of incident prostate cancer in Adventist Health Study–2 – American Journal of Clinical Nutrition (link to abstract – $ for full-text)

 

RCT: Abiraterone and Olaparib for metastatic castration-resistant prostate cancer.

9 Jun, 2022 | 10:21h | UTC

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer – NEJM Evidence

 

Commentary on Twitter

 

Circulating tumor DNA as a biomarker in patients with stage III and IV Wilms tumor.

8 Jun, 2022 | 10:43h | UTC

Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children’s Oncology Group Trial, AREN0533 – Journal of Clinical Oncology

Commentary: Analysis of Circulating Tumor DNA as a Biomarker in Stage III and IV Wilms Tumor – The ASCO Post

 

Nationwide cohort study: Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.

3 Jun, 2022 | 11:10h | UTC

Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer – International Journal of Cancer

Commentary: ADT for Prostate Cancer: What’s the Risk on the Heart? – Medscape (free registration required)

 

Clinical practice guidelines for penile cancer.

2 Jun, 2022 | 10:57h | UTC

Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association – International Journal of Urology

 

Cohort Study: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer.

1 Jun, 2022 | 10:59h | UTC

News Release: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer – Karolinska Institute

Original Study: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA Oncology (link to abstract – $ for full-text)

Authors Interview: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA

Commentary: Large study finds no increased risk for prostate cancer death with 5-ARI use – medwire News

 

Commentary on Twitter

 

10-yr follow-up of a phase 3 RCT: chemoradiotherapy in muscle-invasive bladder cancer.

30 May, 2022 | 10:52h | UTC

Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial – European Urology

 

Commentary on Twitter

 

Position Paper: Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer.

26 May, 2022 | 10:42h | UTC

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies – ESMO Open

 

Cohort Study: Risk of venous thromboembolism in men with prostate cancer compared with men in the general population.

25 May, 2022 | 11:01h | UTC

Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden – BMJ Open

News Release: Men with prostate cancer have a higher risk of serious blood clots – BMJ

 

Commentary on Twitter

Under a http://creativecommons.org/licenses/by-nc/4.0/ license

 

RCT: The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy.

18 May, 2022 | 10:49h | UTC

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

M-A: Comparison of radiofrequency ablation vs. cryoablation For T1 renal tumors.

18 May, 2022 | 10:25h | UTC

Comparison of Radiofrequency Ablation Versus Cryoablation For T1 Renal Tumors: An Evidence-Based Analysis of Comparative Outcomes – Frontiers in Oncology

 

Cohort Study: Survival outcomes associated with cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma.

17 May, 2022 | 10:41h | UTC

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma – JAMA Network Open

 

Commentary on Twitter

 

RCT: Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer.

16 May, 2022 | 02:35h | UTC

Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial – JAMA

Editorial: Robotic Surgery for Bladder Cancer – JAMA

 

Commentary on Twitter

 

AUA/ASTRO Guideline: Clinically localized prostate cancer.

13 May, 2022 | 11:10h | UTC

Homepage: Clinically Localized Prostate Cancer: AUA/ASTRO Guideline – American Urological Association

Part I: Introduction, Risk Assessment, Staging and Risk-Based Management

Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up

Part III: Principles of Radiation and Future Directions

Related:

Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy – European Urology

Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review – The Journal of Urology

High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial – The Lancet Oncology

German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy – Urologia Internationalis

Therapies for Clinically Localized Prostate Cancer – Agency for Healthcare Research and Quality

Radical prostatectomy versus deferred treatment for localised prostate cancer – Cochrane Library

 

Review: Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inhibitors.

10 May, 2022 | 10:32h | UTC

Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors – CNS Drugs

 

First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment.

6 May, 2022 | 10:27h | UTC

First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment – World Journal of Urology

 

Review: A global approach to improving penile cancer care.

5 May, 2022 | 09:55h | UTC

A global approach to improving penile cancer care – Nature Reviews Urology (if the link is paywalled, try this one)

 

RCT: Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

3 May, 2022 | 10:38h | UTC

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer – Journal of Clinical Oncology

Original Study: ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer – Journal of Clinical Oncology

 

Commentary on Twitter

 

Stay Updated in Your Specialty

No spam, just news.